The Impact of Autoantibodies on Outcomes in Patients with Idiopathic Pulmonary Fibrosis: Post-Hoc Analyses of the Phase III ASCEND Trial

Kulkarni, T., Newton, C. A., Gupta, S., Samara, K., & Bernstein, E. J. (2024). The Impact of Autoantibodies on Outcomes in Patients with Idiopathic Pulmonary Fibrosis: Post-Hoc Analyses of the Phase III ASCEND Trial. Pulmonary Therapy, 10(3), 331–346. https://doi.org/10.1007/s41030-024-00267-x
Authors:
Tejaswini Kulkarni
Chad A Newton
Sachin Gupta
Katerina Samara
Elana J Bernstein
Affiliated Authors:
Elana J Bernstein
Columbia Affiliation:
Author Keywords:
anti-cyclic citrullinated peptide (anti-ccp)
antinuclear antibody (ana)
idiopathic pulmonary fibrosis (ipf)
pirfenidone (pf)
rheumatoid factor (rf)
elink
Publication Type:
Article
Unique ID:
10.1007/s41030-024-00267-x
PMID:
39073523
DOI:
10.1007/s41030-024-00267-x
Journal:
Pulmonary Therapy
Publication Date:
Data Source:
PubMed
Source Link:
View PubMed Record
View Web of Science Record
View Scopus Record

Record Created: